BofA analyst Jason Gerberry downgraded Amphastar to Underperform from Neutral with a price target of $20, down from $25. The firm, which lowered estimates on a more modest outlook for Baqsimi and new product launches, sees limited visibility to reacceleration in growth and few catalysts to drive a re-rating over the next 12-18 months, the analyst tells investors.
